Cole Lannum

SVP Investor Strategy and IR Officer, Mallinckrodt Pharmaceuticals

As Senior Vice President Investor Strategy and Investor Relations Officer for Mallinckrodt Pharmaceuticals, Coleman (Cole) Lannum serves to integrate IR with all corporate strategic functions. He consults with executive management and the Board of Directors on acquisitions, strategic direction, and shareholder value optimization. Cole is charged with strengthening IR communications both internally and throughout the broader investment community.

Prior to joining Mallinckrodt in 2015, Cole led IR at Covidien and Tyco Healthcare for nine years as Vice President and Investor Relations Officer. At Covidien, Cole oversaw IR for both the largest healthcare IPO and the largest medical technology merger in history. He designed Covidien’s IR program from infancy in 2006 and led the effort through the completion of the company’s $100B+ merger with Medtronic in 2015.

Cole’s leadership at Covidien was recognized with an unprecedented number of IR best-in-class awards from 2008-2015 including best investment community meetings, best earnings calls, and best financial reporting. For five consecutive years (2011 to 2015), Covidien’s IR program was recognized by IR Magazine as the best overall Large Cap program in the United States. Cole was also voted Best Investor Relations Officer – Large Cap by the investment community for each of those five years.

Cole has previously held investment leadership roles at Putnam Investments, as well as Boatmen’s Trust and American Express Asset Management (both now part of Columbia Asset Management). Cole holds a Master of Business Administration from Texas A&M University and a Bachelor of Science in Business Administration from Washington University. He has been a Chartered Financial Analyst since 1991. Cole resides in Westwood, MA with his wife and family.